News stories about NuVasive (NASDAQ:NUVA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 48.2658392193769 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- NuVasive (NUVA) versus Insulet (PODD) Head-To-Head Analysis (americanbankingnews.com)
- Why Is NuVasive (NUVA) Up 8.3% Since Last Earnings Report? (finance.yahoo.com)
- Minimally Invasive Surgery Market will Reach at a CAGR of 10.5% from 2013 to 2019 (openpr.com)
- Spinal Trauma Devices Market Analysis by 2025: Top Players Like Medtronic, Stryker, Arthrex, NuVasive, DePuy Synthes, Globus Medical (digitaljournal.com)
- Minimally Invasive Spine Surgery – Worldwide Markets, 2025: Featuring Alliance Spine, Zimmer Biomet, DePuy Synthes, Stryker, Medtronic, NuVasive, and Aesculap Implant Systems … (businesswire.com)
Shares of NUVA stock traded down $0.12 during trading hours on Friday, hitting $70.19. 347,300 shares of the company’s stock traded hands, compared to its average volume of 760,567. The firm has a market capitalization of $3.55 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 1.89 and a beta of 0.58. NuVasive has a 12-month low of $44.62 and a 12-month high of $71.15.
Several analysts have commented on NUVA shares. Needham & Company LLC lowered their price objective on shares of NuVasive from $69.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, August 1st. BidaskClub upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Saturday, May 26th. ValuEngine upgraded shares of NuVasive from a “strong sell” rating to a “sell” rating in a report on Monday, July 30th. Zacks Investment Research lowered shares of NuVasive from a “hold” rating to a “sell” rating in a report on Tuesday, July 3rd. Finally, Cantor Fitzgerald initiated coverage on shares of NuVasive in a report on Thursday, May 31st. They set a “neutral” rating and a $54.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $64.06.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: Trading Strategy Examples and Plans
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.